Navigation Links
Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
Date:4/24/2008

- Findings Published in the British Journal of Hematology -

FREMONT, Calif., April 24 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML) today reported findings from an Ohio State University (OSU) clinical study that indicated that a surface-enhanced laser desorption/ionization time of flight (SELDI-TOF)-based thrombotic thrombocytopenic purpura (TTP) diagnostic test could be used to help estimate the risk of TTP relapses during clinical remission. OSU currently offers the TTP test as a laboratory developed test, based on an exclusive licensing agreement with Vermillion, and for which Vermillion sells OSU supplies and laboratory reagents.

The data -- published recently in the online edition of the British Journal of Haematology -- indicate that use of the test may provide a novel screening strategy to identify patients who may benefit from prophylactic treatment to help prevent relapse of this serious blood disorder. TTP is caused by a deficient activity of the enzyme ADAMTS13, which leads to platelet clumping, red blood cell destruction, and, in serious cases, to neurological abnormalities and renal failure.

"TTP is a life-threatening disease that affects thousands of people each year. The disease is characterized by frequent recurrences, with approximately half of all patients experiencing relapses," said Haifeng M. Wu, M.D., lead investigator of the study and Assistant Professor of Pathology and Medicine and Director of the Clinical Coagulation Laboratory at OSU Medical Center. "The SELDI-TOF technology was instrumental in improving sensitivity for extremely low levels of ADAMTS13, which may be used to help identify patients who could be candidates for prophylactic treatment based upon their increased ri
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
2. Vermillion Receives Award From the Society of Gynecologic Oncologists
3. Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles Snuffy Myers Announces Vitamin D Clinical Trials
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
6. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
7. SuperGens MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib
8. Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges
9. Wayne State University and Oakwood Partner in New Device to Combat Congestive Heart Failure
10. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
11. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... CVS Caremark (NYSE: CVS ) today ... of CVS/pharmacy effective October 1, 2011.  With more than ... and Puerto Rico, CVS/pharmacy is one of the largest ... http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) Cosby, 52, most recently served as ...
... Oncobiologics, Inc. and Fox Chase Cancer Center ... next-generation bi-specific antibody cancer platform with enhanced therapeutic ... is designed to handle multiple targets, representing a ... is now underway, with preclinical studies expected in ...
Cached Medicine Technology:CVS Caremark Appoints Mark S. Cosby as President of CVS/pharmacy 2CVS Caremark Appoints Mark S. Cosby as President of CVS/pharmacy 3Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform 2Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform 3
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/23/2014)... bottom of Alzheimer,s disease has been a rapidly ... In the latest crook in the research road, ... interaction between proteins associated with the disease. The ... Chemical Neuroscience , could have important implications for ... Nieznanski and colleagues explain that for years, research ...
(Date:4/22/2014)... A recently FDA-approved device has been shown to reduce ... as 50 percent. When coupled with an innovative electrode ... device facilitated the complete elimination of seizures in nearly ... decade-long clinical trials. , That,s good news for a ... U.S. living with epilepsy whose seizures can,t be controlled ...
(Date:4/22/2014)... 2014 Researchers at UT Southwestern Medical Center are ... depression . , A team of physician-scientists at ... ghrelin (a hormone with natural anti-depressant properties) works inside ... new treatment for depression in the form of a ... study, published online in April,s issue of Molecular ...
(Date:4/22/2014)... April 22, 2014: The Association for Molecular Pathology ... Journal of Molecular Diagnostics on recommendations for ... and master,s levels of education. The report was ... Task Force of the AMP Training and Education ... need of educating future medical laboratory scientists appropriately ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2
... , ... firm Jackson & Coker ranked #3 on SIA’s 2009 list of “Ten Best Staffing ... , ... December 11, 2009 -- Each year, Staffing Industry Analysts, a premier research and analysts ...
... The Phoenix Business Journal and BestCompaniesAZ, co-founders ... SCAN Health Plan Arizona has been named to the 2009 ... employees, who provided extensive insight into employee life. , SCAN ... culture and work environment that fosters personal and professional growth ...
... estrogen-positive tumors, study found , THURSDAY, Dec. 10 ... tamoxifen can boost survival in postmenopausal women with ... as estrogen receptor-positive, and it,s best given before ... study. , "Chemotherapy with Adriamycin adds to your ...
... , U.S. Rep. Gerry Connolly (D-Va.) Also to ... 10 The Federal Employees Health Benefits Plan (FEHBP) open enrollment period ... (AFGE) "Inside Government" radio program. The show will air on Friday, ... www.federalnewsradio.com and 1500 AM in the ...
... , DETROIT, Dec. 10 African-American political leaders, ... Monday, December 14th to create and implement a ... African-American Community. , "Detroit is leading the nation ... the Rev. Horace Sheffield III, National Board Member and ...
... to prevent recurrence, researchers find , THURSDAY, Dec. 10 ... millions of women to fight osteoporosis also cut the ... a dual role in keeping women healthy. , ... of breast cancer therapy. Our feeling is that bisphosphonates ...
Cached Medicine News:Health News:Jackson & Coker Ranks #3 among “Ten Best Staffing Firms to Work For” 2Health News:Jackson & Coker Ranks #3 among “Ten Best Staffing Firms to Work For” 3Health News:Jackson & Coker Ranks #3 among “Ten Best Staffing Firms to Work For” 4Health News:SCAN Health Plan Arizona Named one of Area's Best Places to Work by the Phoenix Business Journal and BestCompaniesAZ, LLC 2Health News:Adding Chemo to Tamoxifen Helps Some Breast Cancer Patients 2Health News:Adding Chemo to Tamoxifen Helps Some Breast Cancer Patients 3Health News:FEHBP Open Enrollment Period to be Discussed on Special Rebroadcast of 'Inside Government' 2Health News:Black Community Unites Against HIV/AIDS Epidemic 2Health News:Bone Drugs May Beat Back Breast Cancer 2
White Standard Girdle...
Black Spandex Above the Knee Compression Girdles with Contact Closure with Zipper...
Short Girdle, Mid-thigh, Front Closure...
Male Body Shaper, Front Closure...
Medicine Products: